查詢結果分析
來源資料
頁籤選單縮合
| 題 名 | 慢性腎臟病礦物質與骨病變:聚焦於心血管疾病風險評估、治療目標及預防策略=Chronic Kidney Disease-Mineral Bone Disorder: Focus on Cardiovascular Disease Risks, Treatment, and Prevention |
|---|---|
| 作 者 | 林盈萱; 曾千慈; 劉冠宏; 曾進忠; | 書刊名 | 內科學誌 |
| 卷 期 | 36:3 2025.06[民114.06] |
| 頁 次 | 頁181-190 |
| 分類號 | 415.81 |
| 關鍵詞 | 慢性腎臟病礦物質與骨病變; 心血管疾病; 血管鈣化; Chronic kidney disease-mineral bone disease; CKD-MBD; Cardiovascular disease; Vascular calcification; |
| 語 文 | 中文(Chinese) |
| DOI | 10.6314/JIMT.202506_36(3).05 |
| 中文摘要 | 慢性腎臟病礦物質與骨病變(chronic kidney disease-mineral bone disorder, CKD-MBD)是CKD病患常見且重要的併發症,與心血管疾病(cardiovascular disease, CVD)風險高度相關。CKD-MBD的核心病理機轉包含鈣磷失衡、副甲狀腺素(parathyroid hormone, PTH)和纖維母細胞生長因子23(fibroblast growth factor 23, FGF23)代謝異常,導致血管鈣化、內皮細胞功能受損、心臟結構異常。為降低CKD病患的CVD風險,應從早期開始規則監測、追蹤相關礦物質指標,並依照分期將各項指標控制於建議範圍。本篇綜論除了介紹CKD-MBD和CVD的相關機轉和風險,也希望針對這些病患,提供臨床評估、追蹤及治療的建議。 |
| 英文摘要 | Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a common and significant complication in patients with chronic kidney disease (CKD), strongly associated with an increased risk of cardiovascular disease (CVD). The core pathophysiological mechanisms of CKD-MBD include calcium-phosphorus imbalance, abnormal regulation of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), which contribute to vascular calcification, endothelial dysfunction, and cardiac structural abnormalities. Effective reducing the CVD risk in CKD patients requires early and regular monitoring of mineral metabolism markers, alongside maintaining these markers within recommended ranges according to the patient's CKD stage. This review explores the mechanisms linking CKD-MBD and CVD risk and provides clinical recommendations for the evaluation, monitoring, and management of these patients. |
本系統中英文摘要資訊取自各篇刊載內容。